BMS schizophrenia drug wins US approval
October 22, 2003New atypical antipsychotic Abilify has gained FDA approval for the treatment of schizophrenia and is tipped to eventually become a …
National service framework leaders appointed
October 22, 2003Key appointments for the Children's National Service Framework and the Long-term Conditions National Service Framework have been announced.The external working …
Government presses on with MCA merger
October 22, 2003The UK Government is to press ahead with the merger of the Medicines Control Agency and its medical devices counterpart …
Bayer parallel import case reopened
October 22, 2003A landmark legal battle over parallel trade of Bayer's blood pressure treatment Adalat has been re-commenced in the European Court …
New Bextra warnings add to COX-II doubts
October 22, 2003New warnings on the label of second-generation COX-II inhibitor Bextra have added to doubts about the safety of the drug …
Pharmacia man tipped to head Celltech
October 22, 2003Pharmacia's Head of Research and Development, Goran Ando, is tipped to become Celltech's new Chief Executive when its current incumbent …
Pharma marketing’s changing skills set
October 21, 2003Business Services, Sales and Marketing marketing, recruitment, skills
Sales and marketing are undergoing something of a revolution as the pharmaceutical industry reacts to a multitude of challenges. Waning …
New FDA head promises improvements for workforce
October 21, 2003The new FDA Commissioner, Dr Mark McClellan, has pledged that improvements in the working lives of staff will be a …
WTO close to agreeing medicines supply deal
October 21, 2003World Trade Organisation ministers say they are close to striking a deal aimed at improving the provision of medicines to …
Local people to control foundation hospitals
October 21, 2003Local people are to play a major role in deciding how the new, more autonomous foundation hospitals are to be …
‘Smart’ cancer drugs share top honours in drug innovation prize
October 21, 2003prix galien
The innovative science behind two breakthrough cancer drugs, Novartis’ leukaemia treatment Glivec and Roche’s breast cancer drug Herceptin, has been …
Novartis questions AstraZeneca cancer data
October 21, 2003Novartis has questioned the evidence behind a UK licence extension to AstraZeneca breast cancer drug Arimidex.The Medicines Control Agency licence …
Kogan steps down from troubled Schering
October 21, 2003Richard Jay Kogan has stepped down as Chairman of Schering-Plough and will relinquish his post as Chief Executive and President …
Cozaar gains renal protection licence
October 21, 2003Merck Sharpe & Dohme's Cozaar has gained a new UK licence for renal protection in patients with type II diabetes …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
